CD168 antibody targets the CD168 antigen, also known as Receptor for Hyaluronan-Mediated Motility (RHAMM), a non-glycosylated protein encoded by the *HMMR* gene. RHAMM interacts with hyaluronic acid (HA) and signaling pathways (e.g., ERK, MAPK) to regulate cell migration, proliferation, and adhesion. Overexpressed in cancers (breast, colorectal, leukemia), RHAMM correlates with metastasis, poor prognosis, and therapy resistance, making it a biomarker for tumor aggressiveness. CD168 antibodies are widely used in research to detect RHAMM expression via techniques like immunohistochemistry (IHC) and Western blotting, aiding cancer diagnosis and mechanistic studies. Therapeutic potential is explored in blocking RHAMM-HA interactions to inhibit tumor progression or angiogenesis, though clinical applications remain investigational. Antibody specificity varies due to RHAMM isoforms, necessitating validation for experimental consistency.